Key Developments: Magforce AG (MF6G.F)

MF6G.F on Frankfurt Stock Exchange

5.85EUR
22 Jul 2014
Price Change (% chg)

€0.49 (+9.12%)
Prev Close
€5.36
Open
€5.36
Day's High
€5.90
Day's Low
€5.35
Volume
4,400
Avg. Vol
4,057
52-wk High
€6.84
52-wk Low
€2.38

Search Stocks

Latest Key Developments (Source: Significant Developments)

MagForce AG announces enrollment of the first patient in the MF 1001 glioblastoma study at the Muenster University Clinic
Monday, 31 Mar 2014 03:30am EDT 

MagForce AG:Announces the enrollment of the first patient in the MF 1001 clinical study at the Muenster University Clinic.MF 1001 is an open-label, randomized, controlled clinical trial assessing the efficacy and safety of NanoTherm(R) therapy as monotherapy and in combination with radiotherapy compared to radiotherapy alone in glioblastoma patients at first relapse.During NanoTherm(R) therapy, superparamagnetized iron oxide nanoparticles are injected into the tumor and then heated in the alternating magnetic field of the NanoActivator(R) in order to kill the tumor cells.  Full Article

MagForce AG installs NanoActivator at Kiel University Hospital
Thursday, 19 Dec 2013 09:51am EST 

MagForce AG:Announces the installation of the NanoActivator as part of the preparations for the new glioblastoma study at the Kiel University Hospital.  Full Article

MagForce AG Installs NanoActivator at University Hospital Munster
Wednesday, 6 Nov 2013 03:01am EST 

MagForce AG announced the installation of the second NanoActivator. The NanoActivator was brought into operation as part of the preparations for the new glioblastoma study at the University Hospital Munster and is the second after the one at the university hospital Charite in Berlin. The financial terms of the deal were not disclosed.  Full Article

MagForce AG Maintains FY 2013 Financial Guidance
Monday, 30 Sep 2013 06:33am EDT 

MagForce AG announced that based on current developments, the Company is reiterating its outlook for the fiscal year 2013 as published in the 2012 Annual Report. Given the Company's roll-out plan, it expects the net loss from operating activities to be higher than in 2012, largely due to the start of the new clinical glioblastoma study and to preparations for market entry in other countries.  Full Article

MagForce AG Comments on FY 2013 Guidance
Thursday, 27 Jun 2013 02:00am EDT 

MagForce AG announced that the Company cannot be sure whether increasing revenues can be realized in the fiscal year 2013, whereby the Company expects to generate an increasing net loss from operating activities as compared to the fiscal year 2012 as part of its roll-out plan. This will mainly be due to the start of the clinical post-marketing study and preparations for market entry in additional countries. This corresponds to the objectives of the series of measures passed in the fiscal year 2012, the related restructuring of the Company and the focus on strategically important value drivers.  Full Article

MagForce AG Announces Board Change
Friday, 14 Jun 2013 12:56pm EDT 

MagForce AG announced that it has appointed Dr. Ben J. Lipps, former Chief Executive Officer (CEO) and Chairman of Fresenius Medical Care, as Chairman of the Management Board and Chief Executive Officer of the Company starting September 2013. While serving as Chairman and CEO of Magforce, Ben Lipps will continue his consultantship with Fresenius Medical Care. The current management board members of Magforce Prof. Dr. Hoda Tawfik (Chief Developement & Medical Officer) and Christian von Volkmann (Chief Financial Officer) remain in their respective position.  Full Article

MagForce AG Receives BfArM Approval To Start Post-Marketing Study In Glioblastoma With NanoTherm Therapy
Monday, 8 Apr 2013 04:56am EDT 

MagForce AG announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start the post-marketing clinical study in recurrent glioblastoma. The trial is an open-label, randomized, controlled study to determine the efficacy and safety of NanoTherm monotherapy alone and in combination with radiotherapy versus radiotherapy alone in up to 280 glioblastoma patients. It will be conducted in about 15 centers in Germany and will be initially started in five centers, including the University Hospitals Berlin, Duesseldorf, Giessen, Cologne and Muenster. Together with a steering committee of experts in neurooncology, MagForce has designed a study protocol to support and supplement the results of a previous study, which led to the approval of the NanoTherm Therapy and medical devices in brain cancer. In addition, the application procedure of the NanoTherm particles into the tumor should be optimized. This study is also designed to comply with the current guidelines for the development of medicinal products.  Full Article

MagForce AG to Implement a Capital Increase
Friday, 8 Feb 2013 07:05am EST 

MagForce AG announced that it intends to implement a capital increase against cash and noncash contributions including preemptive rights in the total amount of approximately EUR 33.5 million. To achieve this, up to 18,606,553 new no-par value bearer shares will be issued. The capitalization measure was resolved at the Company's extraordinary general meeting on January 25, 2013. Bankhaus Neelmeyer AG, Bremen, will offer the new shares to the Company's shareholders for subscription at a ratio of 2:7. The subscription price for the new shares will be EUR 1.80 per share. The two-week shareholders' subscription period will run from February 14, 2013 to February 28, 2013. Clearstream Banking AG, Frankfurt am Main, will settle the rights for the new shares. The rights will not be traded on the stock exchange.  Full Article

MagForce AG Enters Research Project with University of Bremen for Development of Magnetic Iron Oxid Particles
Thursday, 31 Jan 2013 04:20am EST 

MagForce AG announced that it has entered a research project with the University of Bremen, Center for Environmental Research and Sustainable Technology, for the development of magnetic iron oxid particles with improved efficiency. The particles will allow a more efficient treatment of abdominal cancers, such as prostate and pancreatic cancer. A more efficient magnetic fluid and a pilot manufacturing facility will result from the collaboration. The project will receive funding from the German Mittelstand Innovation Program (ZIM) which is managed by the German Federal Ministry of Economics and Technology and will run for two years.  Full Article

MagForce AG Aims To Raise Up To EUR33.5 Million
Wednesday, 19 Dec 2012 09:49am EST 

MagForce AG announced that the Company, with the approval of the Supervisory Board, has resolved a restructuring plan to safeguard MagForce's long-term existence. Under the plan, the Company's share capital is to be increased by up to EUR18.6 million by granting preemptive rights to shareholders against cash and noncash contributions. The new shares will have a notional value of EUR1.00 and will be issued for EUR1.80. As part of the capital increase, some of the Company's creditors are also to be granted the right to subscribe for new shares at an issue price of EUR1.80 per share against noncash contributions to the extent that shareholders' preemptive rights are disapplied for shares counting as fractions or that preemptive rights have not been exercised following the expiration of the subscription period for all shareholders, but only up to a maximum of 8,933,643 new shares. The rights will not be traded on the stock exchange. The planned capital measures will be proposed to MagForce's shareholders at an extraordinary General Shareholders' Meeting in Berlin on January 25, 2013. In the short to medium term, MagForce will use part of these cash funds to finance the post-marketing glioblastoma study.  Full Article

BRIEF-MagForce expands into the U.S. market

July 22 - Magforce AG : * Says expands into the U.S. market * Says is allowing limited number of selected accredited investors, including

Search Stocks